Study title: Open label, non-comparative study of Cefotaxime (300 mg/kg/day) plus vancomycin (60 mg/kg/day) combination as first line treatment of pneumococcal meningitis in children aged from 3 months to 18 years
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Bacterial Infections and Mycoses | |||||
| Brands: | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: CEFOTAXIME | |||||
| ATC code: | |||||
| Document link: Cefotaxime-Study 1.pdf | |||||
| Document date: 2011-09-23 | |||||
| Study number: FR/94/756/12 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | Y | Y | |